[HTML][HTML] Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus
W Yang, Z Sun, C Hua, Q Wang, W Xu, Q Deng… - Microbes and …, 2018 - Elsevier
Although combination antiretroviral therapy (cART) is highly effective in suppressing human
immunodeficiency virus type 1 (HIV-1) replication, it fails to eradicate the virus from HIV-1-
infected individuals because HIV-1 integrates into the resting CD4+ T cells, establishing
latently infected reservoirs. Histone deacetylation is a key element in regulating HIV-1 latent
infection. Chidamide, a new anticancer drug, is a novel type of selective histone deacetylase
inhibitor. Here we showed that chidamide effectively reactivated HIV-1 latent provirus in …
immunodeficiency virus type 1 (HIV-1) replication, it fails to eradicate the virus from HIV-1-
infected individuals because HIV-1 integrates into the resting CD4+ T cells, establishing
latently infected reservoirs. Histone deacetylation is a key element in regulating HIV-1 latent
infection. Chidamide, a new anticancer drug, is a novel type of selective histone deacetylase
inhibitor. Here we showed that chidamide effectively reactivated HIV-1 latent provirus in …